Drug intelligence / Profile preview

AVC-B-101

Development stage: Preclinical
Lead developer: Avidicure
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics

Overview

AVC-B-101 is a preclinical-stage antibody-drug conjugate (ADC) being developed by Avidicure. It is designed to target B-cell antigens, specifically CD19 and CD20, for the treatment of blood cancers and conditions requiring B-cell depletion. By utilizing the ADC modality, AVC-B-101 aims to deliver a cytotoxic payload directly to malignant or pathogenic B cells, potentially offering a more targeted approach than traditional therapies for hematologic malignancies.

Targets

FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)CD19 (B lymphocyte antigen CD19)CD20 (B-lymphocyte antigen CD20)FCGRT (Neonatal crystallizable fragment receptor)C1Q (Complement C1q)

Beyond the preview

Go deeper on AVC-B-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AVC-B-101.

Explore the full profile